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Summary 
Brain endothelium has a distinctive phenotype, including high expression of transferrin receptor, p-
glycoprotein, claudin-5 and occludin.  Dermal endothelium expresses lower levels of the transferrin 
receptor and it is absent from lung endothelium.  All three endothelia were screened for transcription 
factors that bind the transferrin receptor promoter and show different patterns of binding between the 
endothelia. The transcription factor YY1 has distinct DNA-binding activities in brain endothelium and 
non-brain endothelium. The target-sites on the transferrin receptor promotor for YY1 lie in close 
proximity to those of the transcription initiation complex containing TFIID, so the two transcription 
factors potentially compete or interfere.  Notably,  the DNA-binding activity of TFIID was the 
converse of YY1, in different endothelia.  YY1 knockdown reduced transferrin receptor expression in 
brain endothelium, but not in dermal endothelium implying that YY1 is involved in tissue-specific 
regulation of the transferrin receptor.  Moreover a distinct YY1 variant is present in brain endothelium 
and it associates with Sp3. A model is presented, in which expression from the transferrin receptor 
gene in endothelium requires the activity of both TFIID and Sp3, but whether the gene is transcribed 
in different endothelia, is related to the balance between activating and suppressive forms of YY1. 
 
Running Title:  Transcription factors in endothelium 
 
Abbreviations used: BMEC, bone marrow endothelial cells: DMVEC, dermal microvascular 
endothelial cells: EMSA, electrophoretic mobility shift assay: hCMEC/D3, human cerebral 
microvascular endothelial cell-D3: HTR, human transferrin receptor: LMVEC, lung microvascular 
endothelial cells: pgp-1, p-glycoprotein-1: Sp1, Specific protein-1: TF, transcription factor: YY1, Yin 
Yang 1. 
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Introduction 
 
  Endothelial cells have both barrier properties and selective transport functions. Although all 
endothelial cells share some common properties, they are heterogeneous with respect to their structure, 
protein expression, surface phenotype and secreted molecules depending on their tissue of origin and 
position in the vascular tree. 1-3 Brain endothelial cells which form the blood brain barrier (BBB) are 
coupled by continuous tight junctions of extremely low permeability to hydrophilic substances, which 
are more like those of epithelial barriers. In contrast endothelial cells in non-neural tissues have 
discontinuous tight junctions.4 Central nervous system endothelia display a unique pattern of receptors 
and transporters including transferrin receptor (TR) and p-glycoprotein-1 (pgp-1) in addition to the 
structural proteins occludin and claudin-5. The molecular mechanism controlling expression of the 
different junctional phenotypes and the associated transporters in endothelia is not yet clear.  
  During development, multipotent progenitors differentiate via specific lineages into several 
specialised cell types. Progress has been made in identifying transcription factors required for the 
initial growth and differentiation of endothelium, but much less is known about the factors that control 
the terminal differentiation in different tissues including the brain.5  The 5’ promoter region of genes 
selectively expressed in brain endothelium, including the transferrin receptor, claudin-5, occludin and 
pgp-1, all contain GC-rich segments with common sequence motifs despite their diverse functions and 
locations within the genome. Hence we hypothesised that these genes are under common 
transcriptional control and common transcription factors could act on all these genes to induce their 
expression in brain endothelium.  The approach taken in this programme has been to identify 
transcription factors that are present/active in one type of endothelium but absent or functionally 
inactive in another.  In this study we have focussed on the transcriptional control of the transferrin 
receptor, a potential therapeutic target for delivery of macromolecules across the blood-brain barrier. 6 
   Iron transport across the blood brain barrier involves the transferrin receptor, a cell membrane 
associated glycoprotein that serves as a transporter of iron. 7 These receptors are expressed on other 
cell types but levels vary greatly, 8 and expression is generally low or undetectable on non-brain 
endothelium. Expression of the transferrin receptor may be controlled by a post-translational 
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mechanism in response to iron demand. 9 However control of expression in different cell types appears 
to be at the transcriptional level, 10-14 although little is known about the regulatory mechanisms that 
influence the selective expression of the TR gene in brain endothelial cells. The aim of this study was 
therefore to identify transcription factors which regulate the expression of the transferrin receptor in 
human brain and non-brain endothelium. The human transferrin receptor (HTR) promoter region 
contains potential binding sites for more than 12 transcription factors identified by TRANSFAC.  In an 
initial screening we identified specific protein-1 (Sp1), Yin Yang 1 (YY1) and TFIID as potential 
candidates in controlling the tissue-specific expression of HTR, - binding sites for each of these factors 
are present in the HTR promoter, and the DNA-binding activity of these factors varied greatly between 
the endothelia.   
   YY1 is a bifunctional protein capable of activating or repressing the transcription of many genes 
especially during cell growth and differentiation. 15 YY1 can have a dual activity even on the same 
promoter, depending on the cell type or differentiation state. Sp1 is the prototype of a large family of 
transcription factors. Sp1 itself is generally thought to be a constitutive factor that enhances the 
transcriptional initiation of numerous genes. Saffer et al., 16 found that there are large variations in Sp1 
levels during development and between various tissues, suggesting a regulatory role for Sp1 in growth 
and development.   
    To understand how human endothelial cells vary in transcription factor profile, we examined human 
brain endothelium (hCMEC/D3), 17 primary human dermal microvascular endothelial cells (DMVEC), 
lung microvascular endothelial cells (LMVEC) and a human bone marrow endothelial cell line 
(BMEC). 18 The aim of this work was to identify differences in the expression of transcription factors 
between differentiated endothelia, that could determine the tissue-specific phenotypes of endothelial 
cells and in particular, brain endothelium. Since the blood brain barrier limits the access of many 
potential therapeutic agents into the central nervous system, the identification of transcription factors 
that regulate the phenotype of brain endothelium, could be the basis for modulating their expression in 
vivo, which will allow more effective drug delivery to the central nervous system. 
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Results 
 
Phenotyping of endothelial cells 
HTR expression in brain endothelial cells (hCMEC/D3) was examined by Western blotting and the 
expression levels were compared with that in endothelial cells from non-neural tissues (DMVEC, 
LMVEC). Figure 1 shows that brain endothelial cells express HTR, detected as a band migrating at 95 
kDa. DMVEC had lower expression and very low expression was seen in LMVEC. The results 
confirm that HTR expression differs greatly in the three different endothelial cell types. To confirm 
that the hCMEC/D3 cells maintain the phenotype of brain endothelium, we also examined the 
expression of pgp-1, occludin and claudin-5 by Western blotting. P-glycoprotein-1 was detected at 170 
kDa, claudin-5 at 20-22 kDa  and occludin at 65 kDa  in hCMEC/D3 cells (Figure 1). Lower 
expression of claudin-5 was seen in DMVEC and LMVEC,  and a trace of occludin was detected in 
lung endothelium. 
 
Identification of DNA-binding proteins in different endothelia 
EMSAs were used to detect DNA binding proteins in the nuclear extracts of the three types of 
endothelium, using the 220 bp and 330 bp HTR-promoter gene segments as targets. Figure 2 shows 
that nuclear extracts from hCMEC/D3 cells bind to both gene segments, producing a distinctive high 
molecular weight complex on both segments. Nuclear extracts of DMVEC and LMVEC also bind the 
330 bp fragment (Figure 2 (a)), and to a lesser extent the 220 bp fragment (Figure 2 (b)), but the DNA 
binding proteins are clearly different in the non-brain endothelium. 
   The number of transcription factors in the hCMEC/D3 lysates that bind to the DNA fragments was 
estimated by incubating the nuclear proteins with radiolabelled gene segments in the binding 
conditions as normal, and then UV cross-linking the complexes prior to SDS PAGE.  Figure 2 (c) 
shows that brain endothelium has a single additional band at Mr ~100 kDa which was not present in 
other endothelia.  In addition a specific band at Mr ~30 kDa was seen in the LMVEC nuclear extracts 
binding to the 330 bp fragment. It was not possible to obtain accurate molecular weight values of 
bound TFs from these experiments, since the 330bp radiolabelled target DNA is covalently cross-
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linked to the TFs to allow their detection. The presence of distinct bands in the different endothelia 
shows that different transcription factors are active on the HTR promotor in each endothelial cell type, 
and it suggests that a distinctive high molecular weight TF is active in brain endothelium. 
   To identify which proteins present in the hCMEC/D3 cells could bind to the HTR promoter, a 
transcription factor consensus sequence analysis database, TRANSFAC, was used to search for 
potential transcription factor binding sites in the 330 and 220 base pair fragments. Other studies have 
indicated the role of these segments in transcriptional control of HTR.10 Sequence analysis indicated 
several potential binding sites for known transcription factors, including TFIID, YY1, Sp1, IRF-1, 
CBF, NFAT, SRF, CDP, Pit-1, GATA and c-myb sites. The promoter sequence of HTR and the 
location of potential transcription factor binding sites in the 330 bp fragment is shown in Figure 3. 
Note that the Sp-family consists of over 20 members, of 95-105 kDa in size, each being able to bind 
the same consensus sequence, since they have greater than 90% DNA binding sequence homology.  
  To test whether the different endothelia did in fact contain transcription factors that were capable of 
binding to these regions, consensus oligonucleotide probes containing putative transcription factor 
binding sites were used in EMSAs with nuclear extracts prepared from the different endothelia. For 
the initial characterization we used a panel of oligonucleotides corresponding to the target sequences 
that had been identified in the HTR promotor (Figure 3). The oligonucleotide probes were end labeled 
and used in EMSAs with nuclear proteins from hCMEC/D3, DMVEC, LMVEC and BMEC. We were 
particularly interested to identify probes that showed different EMSA patterns with extracts from 
different endothelia. The probes fell into 3 groups: 
Same for all endothelia: Sp1, IRF-1, CBF, NFAT, SRF, CDP. 
Slight differences: Pit-1, GATA, c-myb 
Major differences: YY1, TFIID (See Figures 5 and 6) 
   The following analysis focuses on YY1 and TFIID, since the initial EMSA screen had shown that 
they were very different in their DNA-binding activity between the endothelia. In addition, we also 
examined the Sp-family of transcription factors, since they appear to be particularly important in 
endothelia, they have a high molecular mass appropriate for the HTR-promoter binding proteins 
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demonstrated by SDS PAGE (Figure 2(c)) and because TFIID interacts with both YY1 and Sp-family 
transcription factors.19-21 
 
Functional activity of Sp-family in endothelia 
We first examined the Sp-family transcription factors. Figure 4(a) shows EMSA analysis of the 
interaction between endothelial nuclear proteins and an Sp-consensus dsDNA probe. The migration on 
the EMSA of a complex containing purified, recombinant Sp1 protein (lane 1) was similar to the 
migration of one band that was observed with the nuclear extracts, which suggests that the slowest 
migrating band is Sp1. A similar pattern of nuclear protein/DNA complexes was produced by all three 
cell types, each showing four distinct major Sp protein/DNA complexes. This indicates that four 
members of the Sp-family of transcription factors are present in all three endothelial cell types studied. 
All complexes were eliminated by the addition of an unlabeled, competitive Sp oligonucleotide, but 
not by an unlabeled, unrelated NFκB oligonucleotide (Figure 4(c)).  
   To identify specific proteins binding to the Sp-consensus oligonucleotide, supershift assays were 
performed with the labeled probe, endothelial cell nuclear proteins, and specific antibodies to Sp1, Sp2 
and Sp3. Figure 4(b) shows that the slowest mobility DNA/protein complex was supershifted by the 
addition of an anti-Sp1 specific antibody, which had no effect on any of the other complexes.  We 
noted that the complex that is supershifted by the anti-Sp1 antibody corresponds to the complex 
formed by purified recombinant Sp1 (Figure 4(a)). An Sp3 specific antibody reduced the intensity of 
the second band and caused the appearance of a supershifted band.  These results confirm that the 
upper band corresponded to Sp1 protein bound to the Sp-consensus oligonucleotide forming a 
protein/DNA complex and the second band to the presence of an Sp3 protein/DNA complex. An Sp2 
antibody had no effect on the pattern of DNA/protein complexes, implying that Sp2 is not present in 
the endothelia. A similar pattern of binding was seen with nuclear proteins from all three endothelial 
cell types, with four DNA binding proteins including Sp1 and Sp3, and two unidentified family 
members in the two faster migrating complexes. 
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Functional activity of YY1 in endothelia 
By scanning the DNA sequence of the HTR promoter fragments we found several candidate binding 
sites for YY1. In order to analyse the specific activity of YY1, EMSAs were carried out in the 
presence of a YY1-consensus dsDNA probe and nuclear extracts from the endothelial cells. For these 
and subsequent experiments, we also used a bone marrow endothelial cell line (BMEC) as an 
additional control since these cells had been immortalised with SV40 large T antigen as was the 
hCMEC/D3 line.  Figure 5(a) shows the autoradiograms of the EMSA with the YY1 DNA/protein 
complexes formed. One distinct protein-DNA-complex was visible after incubation of the BMEC 
nuclear extracts with the YY1 probe. A similar pattern of binding was seen with LMVEC, although 
LMVEC contained a lower level of YY1 DNA binding activity. Only a faint trace of binding was seen 
with hCMEC/D3 and DMVEC extracts. 
   To confirm that the DNA binding protein was YY1, an anti-YY1 antibody was added to the binding 
reaction, which should prevent the formation of the complex or cause a supershift. As seen in Figure 
5(b), formation of the main DNA/protein complex was inhibited and the appearance of a supershifted 
band, was formed by the anti-YY1 antibody confirming the production of a specific YY1/DNA 
complex by BMEC (lane 9) and  LMVEC nuclear extracts (lane 14). Gel shift competition 
experiments were carried out in order to further confirm the specificity of the YY1 DNA-protein 
interactions. An excess of unlabelled competitive oligonucleotide, with a consensus binding site for 
YY1,  inhibited DNA/protein complex formation with BMEC and LMVEC nuclear extracts, (lanes 7 
and 12), but mobility was not inhibited by an excess of an oligonucleotide with an unrelated NF-κB 
site (lanes 10 and 15), indicating that the binding was specific. The faster migrating DNA/protein 
complex was non-specific as it was not inhibited by unlabelled YY1. A mutant YY1 radiolabeled 
oligonucleotide probe mutated in the YY1 consensus sequence failed to interact with any of the 
proteins in the BMEC or LMVEC  nuclear extracts (Figure 5(b)), and no protein/DNA complexes 
were formed.  
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Functional activity of TFIID in endothelia 
Analysis of the endothelial cell nuclear extracts with a TFIID consensus probe in the EMSA showed 
that brain endothelium contains four specific proteins that bind to the TFIID probe (Figure 6(a)). Bone 
marrow endothelium contains one of these proteins, but the three faster-migrating proteins, were either 
greatly reduced or absent.  None of the TFIID-consensus-binding proteins could be detected in 
LMVEC or DMVEC.  Unlabelled, cold competitive TFIID consensus-oligonucleotide inhibited the 
formation of all four bands in the brain endothelium, whereas unlabelled NF-κB had no effect on the 
TFIID DNA binding, confirming the specificity of the DNA/TFIID interaction (Figure 6(b)). Since 
TFIID is a component of the basal transcription machinery, the results suggest that protein(s) in the 
non-brain endothelial nuclear extract, are modulating the functional activity of TFIID. 
 
Subcellular localization of transcription factors by immunofluorescence 
The absence of a YY1/DNA complex in EMSA with the hCMEC/D3 nuclear extracts and the YY1 
consensus probe indicated three possibilities:  
a)  The cells do not express YY1.  
b)  YY1 present in these cells is not capable of binding to the DNA. 
c)  YY1 is present in the cells, but is not localised to the nucleus.  
   In order to determine the amount and localisation of the transcription factors, we carried out 
immunofluorescence on whole cells and western blotting on cell extracts. 
Figure 7 shows the expression of YY1, Sp1 and Sp3 on the three endothelial cell types. All three 
transcription factors are detectable on all three endothelia and show a predominantly nuclear 
localisation. However some cytoplasmic staining was also present (see for example, YY1 staining on 
DMVECs). There appeared to be no variation of these three transcription factors with the cell cycle, 
since recently-divided (paired) cells show similar staining levels to isolated cells. However, the levels 
and profiles of the transcription factors are dependent on the endothelial cell type.  
   We also carried out immunofluorescence for transcription factors in primary human brain 
endothelium (passage 1), to establish whether the results seen with the endothelial cell line were 
representative.  The results in Figure 8 show that the primary brain endothelium also has a high 
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Sp3:Sp1 ratio. YY1 is present in the nucleus of these cells, and the level appears to be higher than in 
the line cells. The predominantly nuclear localisation of all three transcription factors is comparable in 
primary endothelium and the hCMEC3/D3 line.  Although one would ideally carry out all assays with 
primary human brain endothelium, insufficient donor brain tissue was available for EMSAs and 
Western blotting. 
 
Analysis of YY1 isoforms 
Since YY1 protein was shown to be present in nuclei of brain endothelium, we used Western blotting 
to determine whether the YY1 was present in different isoforms in cytosolic and nuclear extracts of 
the endothelia. Figure 9(a) shows comparable levels of YY1 protein expression in cytoplasmic extracts 
from all 4 cell types, as indicated by the presence of a protein of Mr=70kDa that was recognized by 
the YY1 antibody. The hCMEC/D3 cells also expressed a protein of Mr=43kDa that was recognized 
by the anti-YY1 antibody (Figure 9(a)). Since the shorter isoform, seen in brain endothelium was 
detected by antibody to the whole YY-1 (Figure 9(a)), but not by antibody to the C-terminus (Figure 
9(b)), this implies that the short isoform lacks a C-terminal segment. YY1 proteins of these sizes have 
been shown previously by in vitro translation and Western blots, 22 to be YY1 and a truncated form of 
YY1 at the C-terminus, respectively.23 This suggests that in hCMEC/D3 cells YY1 is present, but 
truncation of the YY1 protein  prevents its interaction with DNA  - note that the C-terminus of YY1 
contains its four DNA-binding zinc-fingers.  Taken together, the immunofluorescence data and 
Western blots indicate that YY1 protein is present in hCMEC/D3 cells as well as non-brain 
endothelium, but that the levels and isoforms depend on the cell type.  
 
Functional activity of YY1 in brain endothelium 
Several models have been proposed to account for the alternative actions of YY1 in activating or 
repressing genes,  each of which involve complex interactions with other transcription factors in 
association with the specific target gene. Initially we aimed to establish whether YY1 played any 
functional role in the regulation of the HTR gene. We therefore used RNA interference with siRNA to 
knockdown YY1-mRNA and reduce YY1 expression. Transfection with YY1 siRNA into hCMEC/D3 
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and dermal endothelium led to downregulation of endogenous YY1 protein levels to about 50% of that 
in control cultures as measured by Western blotting (Figure 10). This knockdown of the YY1 gene 
resulted in a decrease in HTR expression in brain endothelium, but only a small decrease was 
observed in dermal endothelium (Figure 10).  Clathrin (used as a house-keeping gene control) was not 
reduced in the brain endothelium by YY1 knockdown (Figure 10).  These results show that YY1 plays 
a role in regulation of HTR expression in brain endothelium 
 
Analysis of Sp-family transcription factors and their interaction with YY1 
We also examined the expression and size of Sp1 and Sp3 proteins by Western blotting in nuclear and 
cytoplasmic extracts.   Proteins of 90-95 kDa and 100-110 kDa were detected for Sp1 and Sp3 
respectively in all four cell types. Moreover there appeared to be additional Sp3 bands in the 
hCMEC/D3 cells, suggesting the Sp3 may have undergone some post-translational modification in 
brain endothelium (Figure 11).   
Because of the proximity of the YY1 and Sp-family target sites in the transferrin-receptor promotor 
(Figure 3),  we examined the possibility that Sp3 was interacting with YY1 in brain endothelium. The 
results of immuno-coprecipitation experiments are shown in figure 12. In these experiments, nuclear 
lysates from different endothelia were precipitated with antibody to one transcription factor and the 
precipitate was then analysed by western blotting for the presence of that transcription factor (positive 
control) or the other transcription factor, as evidence of interaction. (For these experiments, we could 
only use antibodies from rabbit for the precipitation and the blot, consequently the blots all have one 
non-specific band at 55kDa corresponding to rabbit Ig heavy chain). The results show that in 
hCMEC/D3 cells, Sp3 precipitation causes the coprecipitation primarily of the smaller YY1 variants: 
We detected some coprecipitation of YY1 by anti-Sp3 in dermal endothelium, but not lung 
endothelium. The result was confirmed when the coprecipitation was carried out the other way around 
– YY1 precipitation causes coprecipitation, primarily of the larger variant of Sp3 in brain endothelium, 
but not from lung endothelium. Coprecipitation of  Sp3 with anti-YY1 from dermal lysates was barely 
detectable. The results show that there is a strong association of  YY1 and Sp3 in brain endothelium 
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but not in non-brain endothelium. There is some evidence that the interaction preferentially involves 
the shorter variants of YY1 present in brain endothelium. 
 Finally, we attempted to knockdown Sp1 and Sp3 using siRNA (Santa Cruz), however we were 
unable to identify a time/dose that reduced the expression of the transcription factors without killing 
the cells, including conditions that work on other cell types. 
 
Discussion 
 
The broad aim of this investigation was to identify transcription factors that control expression of a set 
of proteins that are present in fully-differentiated brain endothelium. This study focused on HTR, 
which was strongly expressed in hCMEC/D3 and primary brain endothelium, weakly expressed  in 
DMVEC and absent from LMVEC. 
   The HTR gene promoter has binding sites for various transcription factors, including YY1, TFIID 
and Sp1. hCMEC/D3, DMVEC and LMVEC nuclear extracts contained at least four DNA binding 
factors that bind to an Sp1 target, including Sp1 itself and Sp3. Sp1 is the prototype of a family of 
transcription factors that binds GC rich boxes and regulates the expression of many different genes.21 
Sp-family members play an important role in proliferation and differentiation and participate in the 
regulation of genes that are ubiquitously expressed, as well as those expressed in a tissue specific 
manner.24 For example, Sp1 binds to a GC element within the pgp-1 promoter and is required for its 
basal expression in a number of cell lines. 25,26 The complex formed between the 330bp segment and 
hCMEC/D3 nuclear extract indicated a large DNA-binding protein associated with the promotor. Thus 
it is possible that an Sp-family member is a component of this complex. The positioning of Sp1 
relative to that of upstream regulatory elements can be critical for its transcriptional activity. For 
example, Sp1 cooperation with Ets and GATA is required for core promoter transcription of several 
endothelial genes such as ICAM-1. 27 Sp1 generally acts as a transactivator and has been reported to 
act cooperatively at the level of both DNA binding and promoter transactivation .28 
    Regulation of Sp3 transcriptional activity is more complex and it has been described as an activator 
or an inhibitor .21   hCMEC/D3 and primary brain endothelial cells expressed more Sp3 protein than 
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DMVEC, LMVEC or BMEC, with a high Sp3:Sp1 ratio in the nuclear extracts and a distinct form of 
Sp3. Moreover Sp3 competes effectively with Sp1 for DNA-binding binding sites, 29  so one would 
expect  Sp3 to bind preferentially  to the TFR promotor in brain endothelium. Hence, Sp3 is a likely 
candidate as one element in the transcription factor complex required for endothelial HTR gene 
expression.    
   TFIID is a multisubunit complex that initiates transcription. The critical subunit, TATA binding 
protein (TBP), is directly involved in promoter recognition and also has coactivator subunits termed 
TBP-associated factors. In vitro TBP-associated factors act as specific coactivators by direct 
interaction with transcriptional activator proteins such as Sp1.30   Hence, cell-type specific transcription 
is directed by differential activity of TFIID. The TFIID sites in the HTR promoter are in very close 
proximity to the YY1 sites (Figure 3). Moreover, YY1 and TFIID have similar DNA-binding 
requirements. Consequently TFIID and YY1 could compete with each other for HTR promoter 
binding.  Alternatively bound YY1  could prevent other transcriptional activators such as Sp1 or Sp3 
from interacting with TFIID. 
   YY1 is a multi-functional, zinc finger transcription factor, that regulates transcription of many 
cellular genes, acting as either a repressor or activator. Many promoters contain YY1 binding 
sequences, 31,32 and YY1 is known to regulate the  cell cycle and differentiation both in differentiated 
cells, 32,33 and during embryonic development.34  YY1 is subject to complex regulatory mechanisms in 
different cell types which affect its functional activity.35 The promoter sequences surrounding YY1 
binding sites,15 its relative concentration,36 or post translational modifications, 37 can determine 
whether YY1 acts as a repressor or activator. In addition, since the binding motif of YY1 is present in 
a large number of genes, the  regulation conferred by YY1 is probably modulated by association with 
other cell-type specific proteins,31 including various cellular factors and adaptor proteins,35  which are 
themselves, coactivators, corepressors or transcription factors.     
   There are several proposed mechanisms for YY1 mediated repression of transcription. For example, 
YY1 can directly displace a transcriptional activator by binding to an overlapping DNA segment.20  
This mechanism has been demonstrated in the HPV-16 long control region, where YY1  competes 
with Sp1.38  The proximity of the YY1 and TFIID sites in the HTR promoter suggests that direct 
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competition for DNA-binding could occur, and that active YY1 in LMVEC could displace TFIID and 
thereby repress the transferrin receptor gene in these cells.  However, YY1 is also present in the 
nucleii of brain endothelium (Figures 7,8,9) but in this case appears to be functionally inactive (Figure 
5). This raises the question of how YY1 in brain endothelium, differs from that in non-brain 
endothelium.    
   In addition to direct competition for sites on the DNA, it is known that YY1 interacts with a number 
of key transcription factors such as Sp1, 19 TFIID, TBP, 39 myc 32,40 and  ATF/CREB factors 
independently of DNA-binding.41 In addition, this study indicates that YY1 can also interact directly 
with Sp3 (Figure 12).  In many experimental systems YY1 can also activate transcription and it is 
unclear how this is accomplished. Increasingly, evidence shows that YY1 interaction with other Sp 
family members may account for its ability to regulate tissue-restricted gene expression.     
   The presence of two YY1 isoforms, in hCMEC/D3 cells, is consistent with reports of several YY1 
variants in different cells and tissues. 42  This however is the first time that YY1 isoforms have been 
correlated with distinctive cell phenotypes. The truncated form of YY1 in hCMEC/D3 cells lacks the 
C-terminal DNA binding domain, but retains segments that interact with other transcription factors.  
The variant isoforms could explain the different activity of YY1 in brain and non-brain endothelium. 
Alternatively, the ability of YY1 to bind DNA may be modified by phosphorylation or acetylation. 
31,37 The data presented here show that the normal form of YY1, is associated with repression of HTR 
expression in non-brain endothelium, whereas expression of the 45 kDa truncated form in brain 
endothelium is associated with HTR expression. We propose therefore that HTR expression in 
endothelium depends on a balance of activating and repressing forms of YY1. In brain endothelium, 
the YY1 variants preferentially interact with Sp3 and transcription is permitted, whereas in lung 
endothelium the YY1 can bind DNA, and transcription is prevented. Knockdown of YY1 by siRNA in 
brain endothelium disrupts this control system so that repression is favoured and HTR expression 
reduced. 
   In summary, the distinctive characteristics of brain endothelial transcription factors, that potentially 
bind the HTR promotor are: 
a.  Low functional expression of YY1, but high functional expression of TFIID; 
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b.  An isoform of YY1 that lacks the C-terminal zinc-fingers;  
c. Evidence that YY1 levels modulate the expression of HTR in brain endothelium; 
d. A high Sp3;Sp1 ratio, and the presence of a post-translational variant of Sp3; 
e. Evidence that Sp3 interacts with YY1 in brain, but not non-brain endothelium. 
   The data lead us to propose a model with the following characteristics: 
1. Transcriptional activation of HTR depends on TFIID,  in association with Sp3, which is strongly 
expressed and active in brain endothelium. 
2. TFIID and YY1 compete for binding sites in the HTR promoter. 
3. YY1 is expressed in distinct isoforms in different endothelia but only binds its target DNA in the 
HTR promoter in non-brain endothelium.  
4. The balance between activating and repressive variants of YY1 determines whether the HTR gene  
is transcribed in different endothelia. YY1 can directly interact with Sp-family transcription factors, 
but could additionally engage with chromatin-modifying enzymes to establish long-term regulation of 
the endothelial phenotypes. 
   The promoter regions of occludin, claudin-5 and pgp-1 also have target sites for Sp-family 
transcription factors, TFIID and YY1. We therefore suggest that control by  YY1 could be a common 
element in the switch mechanism for several genes which are selectively expressed in brain 
endothelium.   
 
Materials and Methods 
 
Endothelial cell cultures 
We have used an immortalised brain microvascular endothelial cell line, derived from human adult 
brain tissue (hCMEC3/D3). This cell line shows a conserved endothelial cell phenotype and 
expression of BBB markers (transferrin receptor and tight junction proteins, ZO-1, occludin and 
claudin-5). The line also expresses  p-glycoprotein (pgp-1) and breast cancer resistance protein.17 The 
cells were grown on collagen coated plates and maintained in EGM-2–MV medium (Biowhittaker, 
Wokingham, Berks, UK) supplemented with 5% FCS; 0.1% FGF2 and gentamycin; 0.025% VEGF, 
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IGF, EGF and ascorbic acid and 0.01% hydrocortisone. The cells were grown to confluence and rested 
for two days, prior to experiments.  
   Primary human brain endothelium (passage 0-1), was obtained from normal tissue donated by 
individuals undergoing temporal lobe resection for epilepsy, with informed consent. The method for 
isolation of primary cells corresponds to that used to isolate the brain endothelial cells which were 
used to generate the hCMEC3/D3 line17. 
   Dermal and lung endothelium were purchased from Clonetics/Biowhittaker (Wokingham, Berks, 
UK) and grown in EGM-2 MV medium according to the manufacturers recommendations. These 
primary cells are from individual donors and were used at passage 5-8.  The transformed human 
BMEC line was kindly donated by Babette Weksler. 18 The cells were cultured in Dulbecco’s modified 
Eagle medium (Gibco) with low glucose (1 mg/ml) and 2 mM glutamine, supplemented with 10% 
FCS. A detailed description of the culture conditions and characteristics of these cells is given in 
Hillyer et al.3 
 
Amplification of HTR promoter by specific nested PCR. 
One gene segment from the 5’ promoter region of the HTR gene (sequence X05339, position -307 to -
854; see figure 3) was prepared by nested PCR using normal human genomic DNA as a template (25 
µg/ml, Promega). For the first PCR, HTR promoter region specific primer pairs, 5’-CCA AGG CCC 
AGA AAC GGA T-3’, and 5’-GGC CTG AAG GTC AGT TTA TGT GC-3’ from Invitrogen were 
used. PCR was carried out in a reaction mixture containing 10 mM Tris-HCl, 50 mM KCl, 1.5 mM 
MgCl2, 0.2 mM dNTPs, 2 µM of forward and reverse primers, 1U Taq DNA polymerase and 1 µl 
genomic DNA in a total volume of 20 µl. Fragments were amplified with the following PCR cycles: 
94ºC for 5 minutes: 35 cycles of 94ºC for 30 seconds, 55ºC for 30 seconds and 72ºC for 90 seconds, 
and finally 72ºC for 7 minutes. Products of the first round of amplification were diluted 1 in 20 and 
amplified in a second nested PCR with primers 5’-CTA ACC GGC GGT TTA TAG CCT G- 3’ and 
5’-CTG ACC TTG ACC AAC CTC CAG TC-3’, in the same conditions as the first round of PCR, for 
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30 cycles, with a final extension of 72ºC for 10 minutes. The PCR products were separated and 
analysed on a 1% agarose gel, stained with ethidium bromide, and visualised under a UV light. 
   The 550 bp band was excised from the gel, extracted, purified with a Novagen kit and ligated into 
the pCR 2.1-TOPO cloning vector (Invitrogen). After transformation into E coli TOP10F’ bacterial 
cells (Invitrogen), plasmids were screened by digestion with restriction endonucleases and the insert 
was sequenced to confirm its identity. Fragments were released from the vector by flanking restriction 
enzymes. Large scale plasmid preps were purified using a commercially available kit (Qiagen).  The 
550 bp fragment was digested with Acc1, to generate 2 fragments of 220 and 330 bp suitable for use in 
electrophoretic mobility shift assays (EMSA).                                                                                                                     
 
Nuclear protein purification 
Nuclear protein extracts were isolated from cells according to the method of Staal et al.43 Cells were 
grown to confluence and rested for 48 hours, then washed twice in ice cold PBS and scraped into 0.4 
ml of cell lysis buffer (10 mM HEPES, pH 7.8, 10 mM KCl, 2 mM MgCl2, 1 mM DTT, 0.1 mM 
EDTA, 0.4 mM PMSF, 0.2 mM NaF, 0.2 mM Na orthovanadate and protease inhibitors). The cells 
were allowed to swell on ice for 15 minutes before 25 µl of 10% Nonidet P-40 was added, and the 
cells were vortexed vigorously for 15 seconds and centrifuged for 30 seconds in a microcentrifuge. 
The nuclear pellet was resuspended in 50 µl of nuclear extraction buffer (50 mM HEPES, pH 7.8, 50 
mM KCl, 300 mM NaCl, 0.1 mM EDTA, 1 mM PMSF, 10% (v/v) glycerol, 0.2 mM NaF and 0.2 mM 
Na orthovanadate) by pipetting and rotating on a platform (4°C) for 20 minutes. The samples were 
centrifuged for 5 minutes, the supernatants removed and stored at -80°C. The protein concentrations 
were determined using the BioRad protein assay.44 
 
Electrophoretic Mobility Shift Assays (EMSAs) 
Double stranded oligonucleotides containing various transcription consensus sites, obtained 
commercially (Promega or Santa Cruz), or cloned HTR restriction fragments of 220 and 330 base 
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pairs were end-labelled with [γ-32P] ATP (Amersham) using T4 polynucleotide kinase, at 37°C for 30 
minutes. The oligonucleotide sequences were as follows: 
Sp1, 5’-ATTCGATCGGGGCGGGGCGAGC-3’; 
YY1, 5’-CGCTCCCCGGCCATCTTGGCGGCTGGT-3’; 
YY1(mutant),5’-CGCTCCGCGATTATCTTGGCGGCTGGT-3’, with the mutated bases in bold; 
TFIID, 5’-GCAGAGCATATAAAATGAGGTAGGA-3’; 
NF-κB,5’-AGTTGAGGGGACTTTCCCAGGC-3’, with the factor binding sites underlined. 
The labelled double stranded oligonucleotides were purified through a Probe Quant G50 microcolumn 
(Amersham, Bucks) into a final volume of 30 µl. Five micrograms of nuclear extracts were incubated 
in 20 µl DNA binding buffer, containing 20 mM HEPES (pH 7.5), 4% Ficoll, 1 µg of poly (dI-dC), 
0.1 mM MgCl2, 0.1 mM dithiothreitol (DTT)  and 1 µl 32P-end-labelled double stranded 
oligonucleotide probe (about 10, 000 dpm or 10fmol) for 35 minutes at room temperature.  After 
mixing with 1 µl of loading buffer (250 mM Tris-HCL, pH 7.8, 0.2% bromophenol blue, 40% 
glycerol), the resulting DNA/protein complexes were separated from free oligonucleotide, by 
subjecting them to electrophoresis in a precooled and pre-run 4 %, non-denaturing polyacrylamide gel 
(29:1, acrylamide:bisacrylamide) and electrophoresed in 0.25 X TBE buffer,  for 10 minutes at 240 V 
and a further 5 hours at 120 V. Following electrophoresis, the gel was dried under vacuum for 45 
minutes at 80°C, and visualised by autoradiography by exposure to Kodak X-Omat film at -70°C with 
intensifying screens. 
   To determine the specificity of the gel shift complexes, competition studies were performed, 
incubating 200-fold excess of an unlabeled oligonucleotide, in the binding buffer prior to separation of 
the protein/DNA complexes in the polyacrylamide gel. In parallel EMSAs, specific supershift 
antibodies (2 µg) were added to the binding reaction, and incubated for 30 minutes, at room 
temperature prior to the addition of the 32P labelled probes. The Sp1 (PEP2), Sp2, Sp3 and YY-1 
(C20) rabbit polyclonal antibodies were from Santa Cruz Biotechnology (X versions). After this 
incubation, the probe was added and incubated for a further 30 minutes, prior to loading on the gel. 
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UV Cross-linking followed by SDS-PAGE 
Nuclear proteins were incubated with the radiolabeled transferrin receptor promoter fragments in the 
same binding conditions as in  EMSAs, followed by cross linking the protein to its regulatory 
sequence using UV light (40000 µW/cm2 for 50 minutes) and resolving complexes on an 8% SDS 
polyacrylamide gel. After electrophoresis the gel was dried and visualisation was performed by 
autoradiography. 
 
Western Blotting 
Identification of HTR and other endothelial markers was done by Western blotting. Cells were scraped 
into 40 µl SDS sample buffer (125 mM Tris-HCl pH 6.8, 4% sodium dodecylsulfate, 5% glycerol, 50 
mM dithiothreitol, 1 mM orthovanadate, 0.05 µg/ml bromophenol blue) at 4°C. Protein concentration 
was measured by the Biorad protein assay and samples heated at 95 °C for 5-10 minutes. Equal 
amounts (20 µg) of cell lysates were resolved by an 8% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) in non-reducing conditions. Proteins were electroblotted onto BA23 
nitrocellulose membrane (Schleicher & Schuell, Keene, NH, USA) at 0.15 mA overnight at 4°C. 
Membranes were blocked in 5% non-fat dried milk at room temperature in PBS containing 0.05% 
Tween 20, for 2 hours. Membranes were washed and subsequently incubated with 1 in 1000 dilution 
of primary antibody in blocking buffer for 2 hours at room temperature.  Antibodies to HTR, occludin 
and claudin-5 were from Zymed. Anti-pgp-1 (C219) was from Merck Biosciences. Polyclonal rabbit 
anti-YY1 antibodies were purchased from Santa Cruz Biotechnology; C20 was raised against the C-
terminal 20 residues while H414 was raised against full length YY1 protein. Polyclonal rabbit anti-
Sp1 and Sp3 antibodies were purchased from Santa Cruz. After exhaustive washing in PBS containing 
0.05% Tween-20, membranes were incubated in 1:15,000 secondary antibody in blocking buffer for 1 
hour at room temperature, -  HRP-conjugated goat anti-rabbit or anti-mouse IgG (Pierce, Chester, 
UK), as appropriate. Membranes were washed with 6 changes of PBS containing 0.05% Tween-20 
and once with PBS alone.  Immunoblots were visualised by enhanced chemiluminescence (ECL, 
Amersham, Bucks,UK).  
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Immuno-coprecipitation assays 
Confluent hCMEC3/D3, dermal or lung endothelial cell monolayers were scraped into 1ml of 
ice-cold RIPA lysis buffer (Sigma, Dorset, UK) and held at 4°C for 15 min. The lysates were 
then centrifuged at 14000 rpm for 15 min to remove cell debris. Lysates were 
immunoprecipitated overnight at 4°C with protein G beads (Pierce, Chester, UK) previously 
incubated for 1 h at 4°C with specific antibody. After three washes in RIPA lysis buffer, 
beads were resuspended in SDS sample buffer and the immune complexes separated on 10% 
SDS-PAGE gels and proteins detected by western blotting. 
 
Immunofluorescence confocal microscopy and image analysis 
Cells grown on collagen coated coverslips, were rinsed three times with cold PBS and fixed at room 
temperature with 4% paraformaldehyde in PBS for 10 minutes. After three washes in PBS, cells were 
permeabilised with 0.2% Triton X-100 in PBS for 10 minutes and then incubated with 0.2µg of either 
Sp1, Sp3 or YY1 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) for 1 hour. Cells were 
washed extensively and incubated with the appropriate FITC-conjugated secondary antibody (Vector 
Labs, Burlingame, CA). After three PBS washes, the coverslips were mounted in Dako fluorescent 
mounting medium (Dako Corp, Carpinteria, CA) and fluorescent images obtained with a confocal 
microscope Leica TCS (Leica Microsystems, Mannheim, Germany). After correction for background 
intensity, boxes were drawn around the nucleii of each cell and the mean pixel intensity was 
determined on a scale 0-255.  This measurement was repeated for ~40 cells each from three 
experiments done on different days. 
 
Cell culture with small interfering RNA (siRNA) 
All siRNA reagents were from Santa Cruz Biotechnology and were used according to the 
manufacturer’s recommended protocols and concentrations.  The human YY1 siRNA was a 20-25 
target specific nucleotide. Twenty four hours before transfection hCMEC/D3 cells or dermal 
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endothelium were plated on collagen coated 6 well dishes at 50-60% confluency, in growth medium 
without antibiotics.  48 hours after incubation at 37°C with the YY1 siRNA complex, protein lysates 
were extracted from the cells. mRNA silencing was confirmed by Western blots  with  a YY1 specific 
antibody.  Preliminary analysis had shown that YY1 reduction was optimal at 48 hours after treatment. 
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Legends 
 
Figure 1. 
Western blot analysis of  endothelial cell lysates from HCMEC/D3 brain endothelium (B), DMVECs 
(D) and LMVECs (L) resolved by 8% SDS PAGE, under non-reducing conditions. 20µg of protein 
was loaded on each lane. Blots were probed for tranferrin receptor (TFR), p-glycoprotein-1 (pgp-1) 
occludin and claudin-5. Arrows indicate the expected Mr of each of these markers. Blots were stripped 
and reprobed for actin or Akt as loading conrols, shown below each blot. 
 
Figure 2. 
Analysis of DNA-binding proteins in nuclear extracts of HCMEC/D3 (B), DMVEC (D) LMVEC (L) 
and bone marrow (bm) endothelium. EMSA was performed with dsDNA probes of 330 bp (a) and 220 
bp (b) spanning the human transferrin promotor. A distinctive DNA/protein complex (arrowed) is 
present in brain endothelium using both probes. The position of free probe (FP) is indicated. Lane 1 on 
each gel is a negative control without protein (-). Protein/DNA complexes formed by UV-cross-
linking the 330 bp probe to the nuclear extracts were resolved by 8% SDS PAGE and autoradiography 
(c). A brain specific (*) and a lung specific (**) band are arrowed. 
 
Figure 3. 
Human transferrin receptor promoter region, indicating the position of the 330 bp and 220 bp gene 
segments and location of known transcription factor binding sites. 
 
Figure 4. 
(a) Binding of nuclear extracts from brain (B) dermal (D) and lung (L) endothelium to an Sp-
consensus oligonucleotide analysed by EMSA compared with the shift produced by recombinant Sp1 
protein (rSp1).  Four Sp-family members were identified (arrows). 
(b) EMSA of an Sp-consensus oligonucleotide alone (-) or in the presence of recombinant Sp-1 (rSP1), 
or brain nuclear extract (B) and in the presence of an unlabelled competitive oligonucleotide Sp1, or  
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an unlabelled non-competitive oligonucleotide NFκB. The Sp1 oligonucleotide competes with all four 
Sp-family bands in the brain nuclear extract, but binding was unaffected by NFκB oligonucleotide. 
(c) Identification of individual members of the Sp family of transcription factors by EMSA and 
antibody-induced supershift. Nuclear extracts from brain  dermal  and lung  endothelium were 
incubated with an Sp-consensus oligonucleotide and antibodies to Sp1, Sp2, Sp3 or no antibody (-). 
The position of bands supershifted by the Sp1 antibody and the Sp3 antibody are arrowed. Antibody to 
Sp2 did not shift any of the bands generated by the endothelial nuclear proteins. 
 
Figure 5. 
(a) Binding of nuclear extracts from brain (B) dermal (D), lung (L) and bone marrow (bm) 
endothelium to a YY1-consensus probe, analysed by EMSA. FP indicates free probe. The bold arrow 
indicates a specific YY-/DNA complex. 
(b) Binding of nuclear extracts from brain endothelium (lanes 1-5),  bone marrow endothelium (lanes 
6-10) and lung endothelium (lanes 11-15) to  a YY-1-consensus probe either alone (lanes 1, 6, 11) or 
in the presence of  excess cold YY1-consensus inhibitor (lanes 2,7,12) or a control NF-κB-binding 
oligonucleotide (lanes 5,10,15). A mutated YY-1 probe (lanes 3,8,13) did not form complexes with the 
nuclear proteins.  Inclusion of antibody to YY-1 generated a super-shifted band (*), when 
preincubated with the protein/YY1-probe complexes (lanes 4,9,14). Arrow indicates the YY1-specific 
complexes and NS indicates a non-specific band. 
 
 
 
Figure 6 
(a) Binding of nuclear extracts of brain (B) dermal (D), lung (L) and bone marrow (bm) endothelium 
to a TFIID-consensus probe, analysed by EMSA. FP indicates free probe. Four bands containing 
different isoforms present in brain endothelium are indicated.  
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(b) Inhibition of electrophoretic mobility shift by cold TFIID oligonucleotide (lane 3) compared with 
non-competitive cold NF-kB oligonucleotide (lane 2) and no inhibitor (lane 1). 
 
Figure 7 
Expression of transcription factors in brain (B) lung (L) and dermal (D) endothelium using 
immunofluorescence confocal microscopy:  Cells were rested for two days after reaching confluence 
and were then stained with antibodies to Sp1, Sp3 or full length YY1 (H414). Normal rabbit IgG 
served as a negative control. Data shown is representative of 3 independent experiments. The 
histogram  shows average pixel densities plotted in arbitrary units for the different transcription factors 
in the three cell lines. 
 
Figure 8 
Expression of transcription factors Sp1, Sp3 and YY1 in primary human brain endothelium stained in 
parallel. Data shown is representative of 2 independent experiments. 
 
Figure  9 
Western blots of cytoplasmic (Cyt) and nuclear (Nuc) extracts of brain (B), dermal (D), lung (L) and 
bone marrow (bm) endothelium (20µg of protein per lane) stained with antibody H414 (a) against full 
length human YY1 and antibody C-20 (b) against a carboxy-terminal peptide of human YY1.  Arrow 
indicates the full-length YY1 (70 kDa). * indicates a C-terminal truncated form of YY1 (~45 kDa) 
found only in brain endothelium. ** indicates a C-terminal truncated form of YY1 (~60 kDa) found 
only in lung endothelium. 
 
Figure 10 
Western blot analysis of  proteins (20µg per lane) in dermal (D) and brain (B) endothelium 
(hCMEC/D3) using cells treated for 48hours with siRNA to knockdown YY1 expression, in 
comparison with control cells treated identically, but without the siRNA.   Expression of YY1, 
transferrin receptor (HTR) and clathrin was measured on the same preparation by sequentially 
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staining, stripping and reprobing the blots. YY1 knockdown substantially eliminates HTR expression 
in brain endothelium but reduction of expression in dermal endothelium is limited.  
 
Figure 11 
Western blots of cytoplasmic (Cyt) and nuclear (Nuc) extracts of brain (B), dermal (D), lung (L) and 
bone marrow (bm) endothelium stained with antibody to Sp3. 20µg of protein was loaded on each 
lane.  Arrow indicates expected position of bands. 
 
Figure 12 
Cell lysates of hCMEC/D3 cells (D3), lung and dermal endothelium were immunoprecipitated with 
protein-G beads coated with normal rabbit IgG (RbIgG, control) or with antibody to transcription 
factors (Sp3 or YY1). Whole cell lysates (WCL) were used as positive control to confirm the 
size/presence of the transcription factor in each cell type. The precipitates were examined by western 
blotting for the presence of Sp3 or YY1.  The upper 6 blocks show experiments in which 
immunoprecipitation was with anti-Sp3, to detect coprecipitation of YY1; the lower 6 blocks show 
experiments in which immunoprecipitation was carried out with anti-YY1 to detect coprecipitation of 
Sp3. Arrows indicate evidence of coprecipitation, seen in the centre lane of each block. 
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